BofA/Merrill Lynch Upgrades Eli Lilly (LLY) to Buy, Adds to US 1 List

BofA/Merrill Lynch upgraded Eli Lilly (NYSE: LLY) from Neutral to Buy with a price target of $101.00 (from $74.00). The stock was also added to the firms' US 1 conviction buy list. Analyst Colin Bristow increased estimates for several pipeline products, and he sees upward revisions to pipeline estimates over the next 6-12 months.

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $82.26 yesterday.

You May Also Be Interested In

• Senate Committee Investigates Ozempic and Wegovy Costs - NYT
• RBC Capital Upgrades Galp Energia SGPS SA (GALP:LI) (GLPEF) to Outperform
• Summit Insights Downgrades Silicon Labs (SLAB) to Hold, 'expect its stock to be an inline performer'